Novavax, Inc.
NVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | -70.6% | -64.1% | 654.9% | – |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 69.5% | 94.1% | 97.9% | 58.5% |
| EBITDA | -$0 | $0 | $1 | -$0 |
| % Margin | -271.1% | 50.4% | 80.1% | -60.6% |
| Net Income | -$0 | $0 | $1 | -$0 |
| % Margin | -287.3% | 44.5% | 77.8% | -91.8% |
| EPS Diluted | -1.25 | 0.6 | 2.93 | -0.51 |
| % Growth | -308.3% | -79.5% | 674.5% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |